-
Index hide
According to Statista, It is estimated that by 2027 the market value of stem cell trials in Latin America will reach 281.64 million dollars.
-
The total global stem cell market was valued at about US$6.87 billion in 2016.
-
According to Statista, The total global cell therapy market is projected to reach around $11 billion by 2029.
A team of researchers from the Bellvitge Biomedical Research Institute (Idibell) has shown that transplanting blood stem cells previously treated with a drug that enhances their regenerative capacity can extend life expectancy in mice.
The study, also carried out by scientists from the Clinical Translation Program in Regenerative Medicine of Catalonia (northeast), in collaboration with the University of Ulm (Germany), has been published in the journal Regenerative Medicine of the Nature group, Idibell explained on Tuesday.
“This work provides the first proof of concept that increasing the regenerative potential of aged endogenous stem cells could represent an important strategy to rejuvenate tissues and improve health and life expectancy in older people,” highlighted the leader of the project, Carolina Florian.
In this regard, he has pointed out that aging is associated with a decrease in tissue regeneration caused by the depletion of stem cells. The results of the study show how the rejuvenation of these cells could represent an effective strategy to improve the aging of the whole organism, since it seems that their stimulation could be enough to rejuvenate everything.
The drug used in this study to rejuvenate stem cells is called CASIN, an inhibitor of a Cdc42 protein. The results reveal that the treatment of stem cells with this inhibitor stimulates their regeneration and, consequently, their transplantation improves life expectancy in mice.
Related notes:
